Menu Search
Equities

Anika Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AKP:FRA

Anika Therapeutics Inc

Actions
  • Price (EUR)8.30
  • Today's Change-0.20 / -2.35%
  • Shares traded589.00
  • 1 Year change-50.89%
  • Beta0.3990
Data delayed at least 15 minutes, as of Feb 13 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.

  • Revenue in USD (TTM)82.20m
  • Net income in USD13.91m
  • Incorporated2018
  • Employees288.00
  • Location
    Anika Therapeutics Inc32 Wiggins AveBEDFORD 01730-2315United StatesUSA
  • Phone+1 (781) 457-9000
  • Fax+1 (781) 305-9720
  • Websitehttps://anika.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.